Human genomics doesn't fully explain varied patient responses. The microbiome, up to 90% different between individuals (vs. 99.9% shared human DNA), is a critical missing factor. It interacts with drugs and influences treatment efficacy, representing a new frontier for personalized medicine.
The first wave of microbiome companies failed because the technology wasn't ready. Now, advanced cloud computing and ML can handle the microbiome's vast complexity. Crucially, metabolomics has matured, allowing analysis of what microbes *do* (function), not just who they are (composition), making the data actionable.
Outpost Bio integrates a wet lab with its AI platform to generate proprietary, high-quality data. This is crucial in microbiology, where reproducibility is a challenge. This vertical integration creates a "gold standard" dataset for model training and allows for experimental validation of AI-driven predictions in a closed loop.
As a female founder, Jenny Yang's strategy is to focus on producing exceptional work, forcing judgment based on merit. More importantly, she advises that anyone who judges based on demographics isn't the right person to work with anyway, effectively using this as a filter to build a higher-quality professional network.
Jenny Yang cites physicist Richard Feynman's idea that "the easiest people to fool are ourselves." She applies this to biotech by stressing the need for extreme scientific rigor. Innovators must actively challenge their own results and avoid confirmation bias, especially when developing technologies that impact human health.